Table 1.
Characteristics of the sample cohorts whose serum was used in this study.
| HC | DM | ALS-SP | ALS-FP | |
|---|---|---|---|---|
| Number of patients | 18 | 8 | 24 | 16 |
| Sex (M/F) | 9/9 | 8/0 | 21/3 | 12/4 |
| Age (year) | 58.3 | 58.8 | 58.8 | 64.6 |
| (35 − 70) | (36 − 82) | (46 − 76) | (46 − 81) | |
| Progression rate | – | – | 0.32 | 1.25 |
| (0.05 − 0.6) | (0.6 − 5.1) | |||
| Mean disease duration (month) | – | – | 30.8 | 13.0 |
| (5.3 − 88.5) | (2.37 − 25.5) | |||
| Onset (spinal/bulbar/both) | – | – | 15/7/0 | 11/5/0 |
| Genetic cases | – | – | C9orf72 (2) | C9orf72 (1) |
| SOD1 (1) |
HC: healthy controls; NC: neurological controls; DM: disease mimics; ALS-SP: slow-progressing ALS patients; ALS-FP: fast-progressing ALS patients; M/F: male/female.